Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT04195698. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.
Study identification
- NCT ID
- NCT04195698
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 475 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 15, 2020 (Actual)
- Primary completion
- Sep 11, 2023 (Actual)
- Completion
- Sep 11, 2023 (Actual)
- Last update posted
- Jan 9, 2025
2020 – 2023
United States locations
- U.S. sites
- 33
- U.S. states
- 18
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences /ID# 221021 | Little Rock | Arkansas | 72205 | — |
| Duplicate_First OC Dermatology Research Inc /ID# 218619 | Fountain Valley | California | 92708-3701 | — |
| UCSF Fresno /ID# 218453 | Fresno | California | 93701-2302 | — |
| California Allergy and Asthma Medical Group /ID# 218635 | Los Angeles | California | 90025-7014 | — |
| Dermatology Research Associates /ID# 218637 | Los Angeles | California | 90045 | — |
| Dermatology Clinical Trials /ID# 218627 | Newport Beach | California | 92660-7853 | — |
| Duplicate_UC Davis Health /ID# 218582 | Sacramento | California | 95816-3300 | — |
| Ucsd /Id# 218629 | San Diego | California | 92103 | — |
| Clinical Science Institute /ID# 218632 | Santa Monica | California | 90404-2102 | — |
| Miami Dermatology and Laser Institute /ID# 218664 | Miami | Florida | 33173-3570 | — |
| Florida International Rsrch cr /ID# 218663 | Miami | Florida | 33173 | — |
| GCP Research /ID# 218665 | St. Petersburg | Florida | 33705 | — |
| Clinical Research Trials of Florida, Inc. /ID# 218438 | Tampa | Florida | 33607 | — |
| Georgia Pollens Clinical Research Centers, Inc /ID# 218441 | Albany | Georgia | 31707-1282 | — |
| Medical Dermatology Associates of Chicago /ID# 218551 | Chicago | Illinois | 60654-6903 | — |
| Sneeze, Wheeze, & Itch Associates, LLC /ID# 218552 | Normal | Illinois | 61761 | — |
| Dawes Fretzin, LLC /ID# 218478 | Indianapolis | Indiana | 46256 | — |
| Beacon Clinical Research, LLC /ID# 218636 | Quincy | Massachusetts | 02169 | — |
| Duplicate_Michigan Center for Research Company /ID# 218577 | Clarkston | Michigan | 48346 | — |
| Henry Ford Medical Center - New Center One /ID# 218575 | Detroit | Michigan | 48202-3046 | — |
| Duplicate_Allergy, Asthma & Immunology Associates, PC /ID# 218548 | Lincoln | Nebraska | 68505-2343 | — |
| Skin Specialists, PC /ID# 218549 | Omaha | Nebraska | 68144 | — |
| University Hospitals Case Medical Center /ID# 218574 | Cleveland | Ohio | 44106 | — |
| Southside Dermatology /ID# 218477 | Tulsa | Oklahoma | 74132 | — |
| Oregon Medical Research Center /ID# 218440 | Portland | Oregon | 97223 | — |
| Oregon Medical Research Center /ID# 218578 | Portland | Oregon | 97239 | — |
| Duplicate_Medical University of South Carolina /ID# 221072 | Charleston | South Carolina | 29425 | — |
| Clinical Research Solutions, LLC /ID# 218447 | Jackson | Tennessee | 38305-2163 | — |
| Orion Clinical Research /ID# 218565 | Austin | Texas | 78759-4100 | — |
| Sante Clinical Research /ID# 218911 | Kerrville | Texas | 78028-9640 | — |
| Clinical Research Partners, LLC /ID# 218480 | Richmond | Virginia | 23220-4459 | — |
| Duplicate_Premier Clinical Research /ID# 218583 | Spokane | Washington | 99202 | — |
| West Virginia Research Inst /ID# 218479 | South Charleston | West Virginia | 25309 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04195698, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 9, 2025 · Synced Oct 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04195698 live on ClinicalTrials.gov.